Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

Clinical trial NCT06488378 · RECRUITING

Trial details

NCT number: NCT06488378
Sponsor: Dana-Farber Cancer Institute
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Breast Cancer PALB2-Mutated Breast Carcinoma HER2-negative Breast Cancer BRCA1 Mutation BRCA2 Mutation

Start date: 2024-08-13
Primary completion: 2026-09-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.